首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1378547

阿片类药物使用障碍市场：依药物类型、给药途径、配销通路和地区

Opioid Use Disorder Market, By Drug Type, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2023年10月20日 | 出版商:

Coherent Market Insights | 英文 198 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计 2023 年全球阿片类药物使用障碍市场规模为 32.4 亿美元，预测期内（2023-2030 年）CAGR为 8.7%。

报告范围		报告详情
基准年	2022年	2023年市场规模	32.4亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期CAGR	8.70%	2030年市场规模预测	58亿美元

图 1. 2023 年全球市场占有率(%)（依药物类型）

天然存在或实验室合成的鸦片类药物，与身体和大脑神经细胞上的鸦片受体相互作用，有助于减轻疼痛。依药物类别，包括处方止痛药、合成鸦片类药物和海洛因。处方阿片类药物用于治疗急性疼痛，例如从受伤或手术中恢復、慢性疼痛、积极的癌症治疗、安宁疗护和临终关怀。许多人在医疗监督下依赖处方阿片类药物。阿片类药物使用障碍是一种慢性、终生疾病，可能造成严重后果，包括残疾、復发和死亡。美沙酮是一种完全阿片受体促效剂，透过与大脑中的 mu-阿片受体结合发挥作用，缓解癫痫发作和戒断症状。

美沙酮为液体形式，必须在医疗监督下每天给药。这也降低了滥用和转移的风险，这对一些患者来说仍然是一个挑战。丁丙诺啡是一种部分鸦片促效剂，可缓解疼痛，但不会产生典型的欣快感。纳曲酮是一种鸦片类药物拮抗，这意味着它可以阻止其他鸦片类药物的作用。口服製剂必须每天服用，而注射缓释性只需每月服用一次即可保持疗效。

市场动态

全球阿片类药物使用障碍市场的成长是由主要市场参与者增加产品推出以扩大产品系列的。例如，2021年12月，全球仿製药和生物仿製药领导者山德士宣布将分销其授权仿製药Narcan （美国。在美国可透过零售药局、医院和其他机构购买。

本研究的主要特点

本报告对全球阿片类药物使用障碍市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR）。
它还强调了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数对全球阿片类药物使用障碍市场的主要参与者进行了分析。
本研究涵盖的主要企业包括 Indivior PLC、Alkermes、Orexo AB、Titan Pharmaceuticals, Inc.、Teva Pharmaceutical Industries Ltd.、Mallinckrodt Pharmaceuticals、BioDelivery Sciences International Inc、Viatris Inc.、Hikma Pharmaceuticals PLC、Camurus AB、Sun Pharmacetical ., Amneal Pharmaceuticals LLC., Purdue Pharma LP, Alvogen, Faran Shimi Pharmaceutical, Novartis AG, Emplicure AB, MODASA Pharmaceuticals Pvt.
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
全球阿片类药物使用障碍市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球阿片类药物使用障碍市场的各种策略矩阵，促进相关人员的决策。

公司简介
- Indivior PLC
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc.
- Hikma Pharmaceuticals PLC
- Camurus AB
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC.
- Purdue Pharma LP
- Alvogen
- Faran Shimi Pharmaceutical
- Novartis AG
- Emplicure AB
- MODASA Pharmaceuticals Pvt. Ltd.
分析师观点

第10章章

参考
调查方法

简介目录

Product Code: CMI4597

Global opioid use disorder market is estimated to be valued at US$ 3.24 Bn in 2023, and is expected to exhibit a CAGR of 8.7% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 3.24 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	8.70%	2030 Value Projection:	US$ 5.8 Bn

Figure 1. Global Opioid Use Disorder Market Share (%), By Drug Type, 2023

Opioids are naturally or synthetically made in laboratories to interact with opioid receptors on the nerve cells in the body and brain, and helps in reducing pain. These are class of drugs that include prescription pain relievers, synthetic opioids, and heroin. Prescription opioids are used to treat acute pain such as recovering from injury or post-surgery, chronic pain, active-phase cancer treatment, palliative care, and end-of-life care. Many people rely on prescription opioids to manage their conditions under the care of a physician. Opioid use disorder is a chronic lifelong disorder, with serious potential consequences including disability, relapses, and death.

Methadone is a full opioid agonist that works by binding to the mu-opioid receptors in the brain to relieve cramps and withdrawal symptoms. It comes in a liquid form that must be administered daily under medical supervision. This makes it challenging for some patients but also reduces abuse and diversion risks. Buprenorphine is a partial opioid agonist that provides pain relief without the typical euphoria. Naltrexone is an opioid antagonist that blocks the effects of other opioids. The oral form must be taken daily while the injectable extended-release version lasts for monthly doses.

Market Dynamics

Global opioid use disorder market growth is driven by increasing product launches by key market players to expand their product portfolio. For instance, in December 2021, Sandoz, a global leader in generic and biosimilar medicines, announced the U.S. launch of its authorized generic of Narcan (naloxone hydrochloride) Nasal Spray 4mg that is used to reverse opioid overdose. It is available to people in the U.S. via retail pharmacies and institutions including hospitals.

Key features of the study:

This report provides an in-depth analysis of the global opioid use disorder market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global opioid use disorder market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Hikma Pharmaceuticals PLC, Camurus AB, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Purdue Pharma LP, Alvogen, Faran Shimi Pharmaceutical, Novartis AG, Emplicure AB, and MODASA Pharmaceuticals Pvt. Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global opioid use disorder market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing global opioid use disorder market

Detailed Segmentation:

By Drug Type:
- Buprenorphine
- Methadone
- Naltrexone
- Others
By Route of Administration:
- Oral
- Parenteral
By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Indivior PLC
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc.
- Hikma Pharmaceuticals PLC
- Camurus AB
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC.
- Purdue Pharma LP
- Alvogen
- Faran Shimi Pharmaceutical
- Novartis AG
- Emplicure AB
- MODASA Pharmaceuticals Pvt. Ltd.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Recent Test Launches
Product Launches/Approvals
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Opioid Use Disorder Market, - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Opioid Use Disorder Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Buprenorphine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Methadone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Naltrexone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

6. Global Opioid Use Disorder Market, By Route of Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

7. Global Opioid Use Disorder Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Opioid Use Disorder Market, By Region, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Indivior PLC
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Alkermes
- Orexo AB
- Titan Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- BioDelivery Sciences International Inc.
- Viatris Inc.
- Hikma Pharmaceuticals PLC
- Camurus AB
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC.
- Purdue Pharma LP
- Alvogen
- Faran Shimi Pharmaceutical
- Novartis AG
- Emplicure AB
- MODASA Pharmaceuticals Pvt. Ltd.
Analysts' Views